Human Genome Sciences

Article Abstract:

A comparative analysis of the company sales and financial details of Human Genome Sciences, Inc. from 1994 to 2003 are illustrated. Projections of the annual total returns, revenues and the assets position of the company for the period 2007-09 are made using value line estimates.

Author: Costanza, Andre J.

Publisher: Value Line Publishing, Inc.
Publication Name: The Value Line Investment Survey (Part 3 - Ratings & Reports)
Subject: Business, general
ISSN: 0042-2401
Year: 2004

Drugs, Human Genome Sciences Inc., HGSI

User Contributions:

Comment about this article or add new information about this topic:

Genzyme General

Article Abstract:

Revenues of Genzyme General, a division of Genzyme Corp., from sales of Cerezyme and Renagel will heavily influence shareprice in the the near term. Timely stock long-term capital gains potential out to 2006 and 2008. is affected competitive generic by Oxford GlycoScience .

Author: Butler, Jeremy J.

Publisher: Value Line Publishing, Inc.
Publication Name: The Value Line Investment Survey (Part 3 - Ratings & Reports)
Subject: Business, general
ISSN: 0042-2401
Year: 2003

Forecasts, trends, outlooks, Marketing procedures, Financial management, Labor Distribution by Employer, Finance, Marketing, Company investment, Investments, Statistics, Company marketing practices, Company business forecast/projection, Company forecasts, Genzyme General Corp., Cerezyme (Medication), RenaGel (Medication)

User Contributions:

Comment about this article or add new information about this topic:

Subjects list: United States, Biotechnology industry, Biotechnology industries, Securities, Company sales and earnings, Company earnings/profit, Company securities

Similar abstracts:

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.

Abstracts

Business, general

Human Genome Sciences

Genzyme General